[Central dopaminergic D1 agonists and treatment of Parkinson disease].
Many theories about dopaminergic function in Parkinson's disease are based upon the effects of the D2 receptor. Standard treatments mostly involve dopaminergic D2 agonists. However, the recent development of dopaminergic D1 agonists should help to clarify the role of the D1 receptor in the treatment of Parkinson's disease. The authors review the physiopathological, behavioural and therapeutic data on D1 agonists administered in animal models and in patients.
Soubrouillard
C
C
Centre de Pharmacologie Clinique et d'Evaluations Thérapeutiques et Laboratoire de Pharmacologie Médicale et Clinique, CHU Timone, Marseille, France.
Lombardo
C
C
Rascol
O
O
Bruguerolle
B
B
Blin
O
O
D000818:Animals; D004195:Disease Models, Animal; D018491:Dopamine Agonists / Q000493:pharmacokinetics / Q000627:therapeutic use*; D006801:Humans; D010300:Parkinson Disease / Q000188:drug therapy* / Q000503:physiopathology; D051381:Rats; D017447:Receptors, Dopamine D1 / Q000145:classification / Q000187:drug effects / Q000502:physiology
D018491:Dopamine Agonists; D017447:Receptors, Dopamine D1